I don’t want or need your advise Milsha , You could not even...

First 69 Last

Share
Profile

Follow
suzuki42

1,537 Posts.

303

06/11/19

13:26

Post #: 41275515
Share

Originally posted by milsha77: ↑

It would have been helpful to all SH, and more transparent, if “closed out” could have been better explained, because we’ve seen that term has been used before.
Your earlier point about the tech being at risk of being quickly superseded is valid, though to be superseded you kinda need to have established some sort of market acceptance. A while back the company sent me a couple of papers for the original studies done with the device, published around 2007/8 I think. Assuming no research since then until now with panco, that’s a hell of a period of development inactivity. In that time, radiation techniques (and chemo) have leapt ahead. The new data for high dose mri guided sabr look good - team in US just reported mOS 20 months with > 70Gy to pancreas, with nothing like the tox problems of older radiotherapy. Genesis care in uk just got themselves MRIdian to treat pancreatic. And now ASTRO expert group just put out guidelines for radiotherapy in pancreatic cancer with quite strong endorsement for SABR.

So how will the OSL device be positioned in a market with more established alternative? Without rapid uplift in further data generation, their sales and marketing efforts post CE will have to rely just on panco for a lengthy period, a safety study of modest size where the efficacy issue isn’t really confirmed. Despite what the company puts in its slides to the market about “superior to comparators”, that’s spin and misleading as there’s no evidence at this stage to show device is superior to any meaningful comparator in a controlled study. My take on this is that if I had this cancer and had to make a choice between something like mri guided sabr or osl device, and assuming cost isn’t a consideration, I’d go for the former. Much more practical experience in health systems with external radiation use and greater evidence base- and no evidence osl device offers better outcomes anyway.

Expand

I don’t want or need your advise Milsha , You could not even realise that Anaemia was really the only thing on that whole list that posed a serious threat to the patient . Let the experts make decisions about what treatments are available for pancreatic cancer patients not you . Please investors do your own research before listening to posters like this

OSL Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

1 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

First 69 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.20		Change -0.030(2.44%)		Mkt cap ! $17.06M

Open	High	Low	Value	Volume
$1.25	$1.25	$1.20	$31.45K	25.57K

Buyers (Bids)

No.	Vol.	Price($)
1	90	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.20	10635	2

View Market Depth

No.	Vol.	Price($)
1	90	1.160
1	14056	1.085
1	7500	1.080
2	19761	1.050
1	2500	1.030

Price($)	Vol.	No.
1.200	10635	2
1.240	1250	1
1.245	2418	1
1.250	46027	1
1.300	1500	1

Last trade - 12.08pm 27/06/2025 (20 minute delay)

OSL (ASX) Chart

I don’t want or need your advise Milsha , You could not even...

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I don’t want or need your advise Milsha , You could not even...

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News